Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2Jessica Shipley, James Beharry, Wei Yeh, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1Jessica Shipley, James Beharry, Wei Yeh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Pageof 11